A propensity score-based inverse probability weighting (IPW) approach was used to adjust for confounders, including age, histological subtype (seminoma vs non-seminoma) and American Joint Committee on Cancer stage (I-III) [5] . Correction for International Germ Cell Cancer Collaborative Group risk group was precluded by the lack of tumour marker availability. Standardized differences among the USA, UK and Germany were calculated to assess covariate balance post-IPW. IPW-adjusted Kaplan-Meier curves and Cox regression analysis were used to compare cancer-specific survival among countries. Sensitivity analysis was undertaken to assess the impact of missing stage data on analyses, by repeating IPW without stage information. Statistical analyses were performed using STATA 14.0 (StataCorp., College Station, TX, USA). Table 1 Baseline characteristics of patients diagnosed with testis cancer in the USA, UK and Germany between 1995 and 2011 with standardized differences pre-and post-propensity score weighting*.
Characteristics
USA UK Germany AJCC, American Joint Committee on Cancer. IPW, inverse probability weighting; IPWÀ,pre-inverse probability weighting; IPW+, post-inverse probability weighting. *Standardized differences <10% are indicative with effectively balanced cohorts [7] .
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Overall, 100 143 men with testis cancer were identified in the USA (n = 31 730; 31.7%), the UK (n = 28 158; 28.1%) and Germany (n = 40 255; 40.2%). After propensity score weighting, the characteristics of the men in these three countries were well balanced: standardized differences in stage and histological subtype were <10% , suggesting well-balanced comparison groups ( Table 1 ). The median (interquartile range) follow-up was 88.2 (44.9-140.0) months. IPW-adjusted Kaplan-Meier curves ( Fig. 1) In the present study we found significantly worse testis cancer-specific survival in the USA than in the UK and Germany. Given excellent cure rates for appropriately treated testis cancer, and given noteworthy differences in the health systems in these countries, the findings are consistent for a role for universal health coverage for outcomes in testis cancer. Our findings corroborate a US study by Markt et al. [6] which found that cancer-specific survival was nearly twofold worse among underinsured (uninsured/Medicaid) US men relative to their privately insured counterparts.
This work is subject to the limitations found in any ecological study, as well as the limitations of observational studies, including primarily unmeasured and uncontrolled confounding. For example, the black population is larger in the USA (12.6%; 6% in SEER testis cancer data) than in the UK (3.0%) or Germany (0.5% Sub-Saharan African, National Census Data), and although the incidence of testis cancer is higher among the white population, biological, social and economic differences may remain between racial groups, which may contribute to disparities in cancer-specific outcomes.
We also acknowledge that variations in cancer registry coding across the USA, UK and Germany must be considered when interpreting the results of this study. For example, completeness of stage information varies among registries; a larger number of patients in the US cohort presented at unknown stage. If a significant proportion of these were in fact of advanced stage, this may have contributed to the increased mortality seen in the USA within the first 3 years. Sensitivity analysis was therefore undertaken and demonstrated no significant difference in IPW without stage information; however, some residual imbalance was noted even after IPW, for example, with regard to age. Another limitation relates to potential differences between the registries themselves. Although the registries are generally considered to be of high quality and have all been validated independently, there may be some differences in coding and accuracy of the registries which may account for the observed differences.
Finally, we accept the potential that 'over-powering', in registry-based research may detect differences of dubious clinical significance; however, given that we are reporting differences in survival of a curable disease, we contend that these are of real clinical significance. Despite these limitations, the data used in the present study are from high-quality cancer registries in developed countries with advanced healthcare systems. Given that nearly all testis cancers are curable if appropriately diagnosed and treated, the disparity in outcomes is striking and suggests a critical area for further research.
